

EVALUATI
ASSAY USE
FOR DIAGNOSIS
BCG VACCINE



FINAL RELEASE
TUBERCULOSIS ANTIGENS
TUBERCULOSIS IN
KELANTAN,

MALAYSIA

by

HAJAR FAUZAN BIN AHMAD

Thesis submitted in fulfilment of the requirements for the
degree of Master of Science

OCTOBER 2013

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iii
LIST OF FIGURES	viii
LIST OF TABLES	x
LIST OF ABBREVIATIONS	xi
ABSTRAK	xiii
ABSTRACT	xiv
CHAPTER 1: INTRODUCTION	1
1.1 The Stigma of Tuberculosis.....	1
1.1.1 The General History of TB.....	1
1.1.2 Transmission of TB.....	2
1.1.3 Pathogenesis of TB.....	3
1.1.4 Epidemiology of TB.....	5
1.1.5 Current Status of TB in Malaysia.....	6
1.2 Causative Agent: MTB	6
1.2.1 General Characteristics of MTB.....	7
1.2.2 Cell Wall Structure	8
1.2.3 Genome and Proteome of MTB	9
1.3 The Host Immune Response to TB.....	11
1.3.1 Innate Immunity against MTB	11
1.3.2 Adaptive Immunity against MTB.....	13
1.4 Control of MTB Infection.....	15
1.4.1 Treatment.....	15
1.4.2 Bacillus Calmette–Guerin (BCG) Vaccination Program	16
1.4.3 Development of New Vaccines	16
1.5 Diagnosis of TB.....	17
1.5.1 Current Practices for TB Diagnosis in Malaysia.....	17
1.5.1(a) Active TB (ATB).....	17
1.5.1(b) Latent TB (LTB).....	18
1.5.2 Conventional Methods of Diagnosis	19
1.5.2(a) Microscopy Examination.....	19
1.5.2(b) Isolation of Mycobacteria by Culture	19
1.5.2(c) Biochemical Tests.....	20
1.5.3 Advanced Methods of Diagnosis.....	21

1. 5.3(a) Advances in the Imaging Diagnosis of TB	21
1. 5.3(b) Nucleic Acid Amplification Techniques (NAAT).....	21
1.6 Immunological Diagnosis	22
1.6.1 Serological Test for Antigens and Antibody Detection	22
1.6.2 Non-serological Tests for Antigen Detection.....	23
1.6.3 Immunochromatographic Test (ICT)	24
1.6.4 Cellular Immunodiagnosis.....	24
1.7 Commercially Available TB Detection Kits (QFT-GIT) based on Cellular Immunodiagnosis	25
1.7.1 Modification of the QFT-GIT Kit	27
1.7.2 Introduction of Additional Potential Antigens to QFT-GIT Kit	27
1.7.2 (a) Ubiquitin (UbGR).....	28
1.7.2 (b) ESAT-6	28
1.7.2 (c) Phos1.....	29
1.7.2 (d) Hsp 16.3	29
1.7.2 (e) Mtb 8.4.....	29
1.8 Rationale of this Study	30
1.9 Objectives of Study.....	33
1.9.1 General Objective.....	33
1.9.2 Specific Objectives.....	33
CHAPTER 2: MATERIALS AND METHODS	35
2.1 Research Methodology	35
2.1.1 Study Design	35
2.1.2 Sample Size	37
2.1.3 Study Participants.....	38
2.1.4 Inclusion and Exclusion Criteria	40
2.1.4 (a) ATB Patients	40
2.1.4 (b) HC Individuals	40
2.2 Instruments, Kits, and Software.....	41
2.3 Gold Standard Diagnosis of TB.....	42
2.3.1 Sputum Collection	42
2.3.1 (a) Materials for Sputum Sampling.....	42
2.3.1 (b) Methods for Sputum Sampling	42
2.3.2 Ziehl-Neelsen Microscopic Examination	43
2.3.2 (a) Reagent Formulae	43

2.3.2 (b) Procedures for Ziehl-Neelsen Microscopic Examination	44
2.3.3 TST	44
2.3.3 (a) Materials and Methods for TST	45
2.3.3 (b) Evaluation and Interpretation of TST	45
2.4 Antigens	45
2.4.1 Bradford Protein Assay	47
2.4.2 SDS-PAGE Analysis	47
2.4.2 (a) Resolving Gel Buffer	48
2.4.2 (b) Stacking Gel Buffer	48
2.4.2 (c) Running Buffer	49
2.4.2 (d) Sample Buffer for SDS-PAGE	49
2.4.2 (e) Coomassie Brilliant Blue Protein Gel Stain	49
2.4.2 (f) 5X Coomassie Destaining Solution	50
2.4.2 (g) Preparation of Resolving (10%) SDS-PAGE	50
2.4.2 (h) Preparation of Stacking (4.5%) SDS-PAGE.....	50
2.4.2 (i) Electrophoresis of SDS-PAGE Gel	51
2.4.3 WB Analysis.....	51
2.4.3 (a) Phosphate-Buffered Saline (PBS).....	51
2.4.3 (b) PBS-T20 Buffer	52
2.4.3 (c) PBS-T80.....	52
2.4.3 (d) 50X Tris-acetate-EDTA (TAE)	52
2.4.3 (e) Staining Buffer for WB.....	53
2.4.3 (f) Towbin Transfer Buffer	53
2.4.3 (g) Skimmed Milk	53
2.4.3 (h) WB Procedures	54
2.4.4 <i>in silico</i> Analyses of VacIII Epitopes	55
2.4.4 (a) T-cell Epitope Prediction	55
2.4.4 (b) Similarity Search for Identical Epitopes to VacIII	55
2.5 Whole Blood Assay	56
2.5.1 Materials and Methods for Blood Sampling	56
2.5.2 Optimization of Antigens Concentration.....	57
2.5.3 Incubation of Blood and Harvesting of Plasma.....	58
2.5.4 Parameters for Storage of Plasma Samples	59
2.6 IFN- γ ELISA with QFT-GIT Kit.....	59
2.6.1 Human IFN- γ Standard.....	60

2.6.1(a) Preparation of Human IFN- γ Standard	60
2.6.1(b) Preparation of Human IFN- γ Standard Curve	60
2.6.2 Preparation of Working Strength Conjugate	61
2.6.3 ELISA Washing Buffer	62
2.6.4 Procedures for Human IFN- γ ELISA	62
2.6.5 Calculations and Test Interpretation of ELISA	64
2.7 Statistical Analyses	66
CHAPTER 3: RESULTS.....	67
3.1 General Characteristics	67
3.1.1 Study participants	67
3.1.2 Clinical Characteristics based on Gold Standard Diagnosis	68
3.2 Protein Analyses	69
3.2.1 Determination of Protein Quality and Concentration.....	69
3.2.2 <i>in silico</i> Analyses.....	72
3.2.2 (a) Population Coverage for VacIII and Ubi-VacIII antigens based on T-cell Epitope Prediction	72
3.2.2 (b) <i>VacIII</i> Epitopes Similarity Search using BLAST	73
3.3 IGRA and Statistical Analyses.....	76
3.3.1 The Optimal Concentration of VacIII and Ubi-VacIII Antigens for Whole Blood Stimulation	76
3.3.2 IFN- γ -producing T-Cell Responses to QFT-GIT, VacIII and Ubi-VacIII in ATB and HC individuals	78
3.3.2(a) The Influence of Stimulating Antigens in Different Groups	78
3.3.2(b) The IFN- γ Responses of ATB and HC Individuals toward each Stimulating Antigen Group	81
3.3.3 Evaluation the Effect of PPD Injection on Subsequent IGRA Analysis	86
3.3.4 Determination of Cut-off Points, Sensitivity, and Specificity for QFT-GIT, VacIII, and Ubi-VacIII Antigens	87
CHAPTER 4: DISCUSSION	90
4.1 The Selection of VacIII and Ubi-VacIII Proteins as an Additional Test to the Current Diagnostic Methods	90
4.2 <i>in silico</i> Prediction of VacIII Epitopes.....	92
4.3 Performance of the Antigens as IGRA	95
4.4 Limitations of the Study.....	99
4.5 Recommendations for Future Research	101
CHAPTER 5: SUMMARY AND CONCLUSION.....	102

REFERENCES.....	103
APPENDIX A – Human Ethical Clearance Letter	119
APPENDIX B – Participant Consent Form.....	123
APPENDIX C – The Details of Population Coverage Study	127
APPENDIX D – Output From the Study of Epitope Homologies	128
APPENDIX E – 2x2 Cross Tabulation Test	132

LIST OF FIGURES

Figure 1	Summary of (A) TB transmission and (B) pathogenesis.....	4
Figure 2	Scanning electron micrograph of the MTB bacillus (Under 15549X magnification).....	7
Figure 3	Structure of the cell wall of mycobacteria.....	8
Figure 4	Circular map of the chromosome of MTB H37Rv.....	10
Figure 5	Summary of innate immunity during TB infection.	13
Figure 6	Summary of adaptive immunity during TB infection.	14
Figure 7	The basis of the QuantiFERON® technology.....	26
Figure 8	Flowchart showing an overview of the research methodology.	34
Figure 9	Illustration maps showing the study locations.....	36
Figure 10	Flow chart showing the number of recruited participants in ATB patients and HC individuals.....	39
Figure 11	Types of QFT-GIT blood collection tubes used in this study. The rubber stoppers are colour coded according to the additive the tube contains;.....	56
Figure 12	The vaccutainer Nil tubes with different antigen concentrations.....	57
Figure 13	Steps for incubation of blood and harvesting of plasma.	59
Figure 14	Steps for preparation of fresh Human IFN- γ Kit Standard for each ELISA session.....	61
Figure 15	The positive smear of MTB stained with Ziehl's carbol fuchsin, methylene blue (1000X magnification).....	68
Figure 16	The negative smear of sputum sample stained with Ziehl's carbol fuchsin, methylene blue (400X magnification).	69
Figure 17	SDS-PAGE for recombinant VacIII and Ubi-VacIII protein.	70
Figure 18	Western blot for recombinant VacIII and Ubi-VacIII protein.....	71
Figure 19	Percentage distribution of the population coverage of VacIII epitope based on HLA Class I and II.....	73
Figure 20	The optimal concentration of recombinant VacIII antigen in stimulation of whole blood.....	76
Figure 21	The optimal concentration of recombinant Ubi-VacIII antigen in stimulation of whole blood.....	77
Figure 22	Scattered graph representing the deviation of IFN- γ concentration of ATB group.....	79
Figure 23	Scattered graph representing the deviation of IFN- γ concentration of HC group.	80
Figure 24	IFN- γ levels (IU/mL) elicited in ATB and HC groups by different types of antigen; A) QFT-GIT, B) VacIII and C) Ubi-VacIII.....	82

Figure 25	The different level of IFN- γ production in ATB patients with different durations of anti-TB treatments.	84
Figure 26	IFN- γ levels (IU/mL) elicited in PPD+ and PPD- of HC group stimulated by different type of antigen.	85
Figure 27	ROC curve analysis for VacIII antigens.	87
Figure 28	ROC curve analysis for Ubi-VacIII antigens.	88

LIST OF TABLES

Table 1	List of instruments, kits, antigens, antibodies and software used in this study.....	41
Table 2	Amino acid sequences for the components of synthetic multivalent VacIII and Ubi-VacIII gene.	46
Table 3	Preparation of working conjugate according to the number of the strips, volume of conjugate and volume of GD.....	62
Table 4	The interpretation of result for QFT-GIT kit.....	65
Table 5	Summary of VacIII epitope homology to other Mycobacteria strains.....	75
Table 6	Evaluating the effect of PPD on the IGRA by using paired t-test.....	86
Table 7	Summary of the ROC analyses:	88
Table 8	The sensitivity and specificity of the antigens.	89
Table 9	Population coverage of VacIII epitopes based on HLA Class I and II.....	127
Table 10	BLAST results.....	128
Table 11	Table of 2x2 Cross Tabulation Test that was used to calculated the sensitivities and specificities of QFT-GIT, VacIII and Ubi-VacIII antigens.	132

LIST OF ABBREVIATIONS

AIDS	Acquired Immune Deficiency Syndrome
ANOVA	One-Way Analysis Of Variance
ATB	Active TB
AUC	Area under Curve
BAL	Bronchoalveolar Lavage
BCG	Bacillus Calmette–Guerin/ Bacille de Calmette et Guérin
CMI	Cell-Mediated Immunity
CR3	Complement Receptor 3
CSF	Cerebrospinal Spinal Fluid
CT	Computed Tomography
DOTS	Directly Observed Therapy Strategy
ECL	Enhanced luminol-based Chemiluminescent
ELISA	Enzyme Linked Immunosorbent Assay
ESAT-6	6-kDa Early Secreted Antigenic Target
HC	Healthy Contact
HCW	Health Care Workers
HIV	Human Immunodeficiency Virus
HLA	Human Leukocyte Antigen
HRP	Horseradish Peroxidase
ICT	Immunochromatographic Test
IFN- γ	Interferon-gamma
IGRA	Interferon Gamma Release Assay
LJ	Lowenstein Jensen

LTB	Latent TB
MDR	Multi-Drug Resistant
MHC	Major Histocompatibility Complex
MTB	<i>Mycobacterium tuberculosis</i>
NAAT	Nucleic Acid Amplification Techniques
NTM	Non Tuberculous Mycobacteria
NF- κ β	nuclear factor-kappa beta
PBMC	Peripheral Blood Mononuclear Cell
PHA	Phytohemagglutinin
PPD	Purified Protein Derivative
QFT-G	QuantiFERON [®] -TB Gold
QFT-GIT	QuantiFERON [®] -TB Gold In Tube
RD	Region of Difference
ROC	Receiver Operating Characteristics
SDS-PAGE	Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis
TB	Tuberculosis
TBIS	TB Information System
tblastn	Translated Basic Local Alignment Sequence Tool
TST	Tuberculin Skin Test
USFDA	US Food and Drug Administration
WB	Western Blot
WHO	World Health Organization

**PENILAIAN KE ATAS ASAI PELEPASAN GAMA INTERFERON (IGRA)
YANG MENGGUNAKAN ANTIGEN-ANTIGEN *Mycobacterium tuberculosis*
UNTUK DIAGNOSIS TUBERKOLOSIS PULMONARI DI KALANGAN
POPULASI YANG DIBERI VAKSIN BCG DI KELANTAN, MALAYSIA**

ABSTRAK

Walaupun Malaysia merupakan antara negara yang mempunyai beban kes tuberkulosis (TB) yang sederhana, namun sejak kebelakangan ini jumlah kes baru telah meningkat. Pencegahan TB berpaksi pada kebolehan mengenal pasti jangkitan ini pada peringkat awal dan pemberian rawatan yang efisien. Asai yang menggunakan QuantiFERON[®]-TB Gold In-Tube (QFT-GIT) telah menunjukkan hasil kepekaan dan kekhususan yang meragukan dalam diagnosis jangkitan TB paru-paru aktif dan TB pendam. Untuk kajian ini, dua antigen yang berasal daripada *Mycobacterium tuberculosis* (MTB) iaitu VacIII dan Ubi-VacIII juga turut diuji bagi mengenal pasti kesan tindak balas antigen tersebut terhadap sel T dalam populasi yang menerima suntikan vaksin BCG. Seramai tiga puluh enam pesakit yang menghidapi TB pulmonari dan 38 individu sihat telah dipilih sebagai kumpulan kawalan dari sebuah hospital di Kelantan untuk diuji melalui kaedah piawai standard dan IGRA. Di dalam populasi yang sudah menerima vaksin BCG, kepekaan dan kekhususan adalah seperti berikut; QFT-GIT (30.4% dan 88.9%), VacIII (47.8% dan 55.6%), dan Ubi-VacIII (30.4% dan 18.5%). Secara keseluruhannya perbandingan antara kaedah piawai standard dan IGRA menunjukkan hubungan yang lemah (nilai $\kappa=0.320$), namun, tindak balas sel-T terhadap antigen-antigen menunjukkan perbezaan statistik yang signifikan ($P<0.001$). Kajian ini telah membuktikan setiap antigen menunjukkan kepekaan dan kekhususan yang rendah, maka dapat disimpulkan bahawa ketiga-tiga antigen ini tidak mampu membezakan pesakit yang menghidapi TB, dan populasi yang sihat. Sungguhpun begitu, QFT-GIT masih menunjukkan kekhususan yang lebih baik berbanding VacIII dan Ubi-VacIII, walaupun kepekaannya tetap rendah disebabkan antigen TB7.7 yang tiada dalam variasi MTB klinikal di Asia Tenggara.

**EVALUATION OF INTERFERON GAMMA RELEASE ASSAY
(IGRA) USING *Mycobacterium tuberculosis* ANTIGENS FOR DIAGNOSIS OF
PULMONARY TUBERCULOSIS IN BCG VACCINATED POPULATION OF
KELANTAN, MALAYSIA**

ABSTRACT

Although Malaysia is an intermediate tuberculosis (TB) burden country, the absolute number of new cases has been increasing recently. Improvement in early diagnosis followed by efficient chemotherapy is the major control strategy for TB. Currently, T-cell based interferon-gamma release assays using *Mycobacterium tuberculosis* (MTB) antigens from QuantiFERON[®]-TB Gold In-Tube (QFT-GIT) assays have shown unclear values in terms of sensitivity and specificity in the diagnoses of active pulmonary and latent TB infections. For this study, two MTB antigens known as VacIII and Ubi-VacIII were evaluated for their diagnostic potential based on dynamic T-cell responses among BCG-vaccinated populations were investigated. Thirty-six patients with active pulmonary TB and 38 healthy controls (HC) from a selected hospital in Kelantan, Malaysia were recruited and tested by using gold standard assays and IGRA. The sensitivity and specificity of QFT-GIT, VacIII and Ubi-VacIII antigens among BCG vaccinated population were 30.4% and 88.9%, 47.8% and 55.6%, and 30.4% and 18.5%, respectively. Even though the overall agreement between IGRA and the gold standards assays showed fairly poor correlation (κ -values=0.320), the T-cell responses against the antigens were considered statistically significant ($P<0.001$). In conclusion, all the 3 antigens were unable to discriminate between TB and HC due to high variability of the sensitivities and specificities they demonstrated. As compared to VacIII and Ubi-VacIII, QFT-GIT showed better specificity however its low sensitivity was expected due to the fact that the TB7.7 antigen is absent in clinical MTB strains of South East Asia.